Original Research

Prescribing patterns of echinocandins in adult patients in a private hospital in Gauteng, South Africa

Anja Grey, Rianda Joubert, Stephan Steyn, Marlene Julyan
Southern African Journal of Infectious Diseases | Vol 38, No 1 | a470 | DOI: https://doi.org/10.4102/sajid.v38i1.470 | © 2023 Anja Grey, Rianda Joubert, Stephan Steyn, Marlene Julyan | This work is licensed under CC Attribution 4.0
Submitted: 19 July 2022 | Published: 14 March 2023

About the author(s)

Anja Grey, Department of Medicine Usage in South Africa, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa
Rianda Joubert, Department of Medicine Usage in South Africa, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa
Stephan Steyn, Centre of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa
Marlene Julyan, Department of Medicine Usage in South Africa, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa

Abstract

Background: Worldwide, the leading cause of invasive candidiasis and the fourth leading cause of hospital-acquired infections are the Candida species (spp.) group. One of the most important tools in fighting such drug-resistant fungi is the appropriate use of antifungal agents.

Objectives: The study aimed to determine echinocandins’ general prescribing patterns and how they are associated with the treatment period.

Method: A quantitative, observational, and descriptive was used, and included patients receiving antifungal treatment in a private hospital in Gauteng, South Africa between 01 January 2015 to 31 December 2015.

Results: Of the 146 patient files included, 102 patients (69.9%) received caspofungin and 44 patients (30.1%) were treated with anidulafungin. For the former, 99 (97.1%) patients received a loading dose (LD) of 70 mg, while 200 mg anidulafungin was only prescribed to 30 patients (68.2%). In line with maintenance dose guidelines, the majority (98.1%) of caspofungin-treated patients received 50 mg IV daily, whereas 4 (3.9%) patients were treated at higher doses (70 mg daily). Anidulafungin was administered at various maintenance doses, including 400 mg (2.3% of patients), 200 mg (52.3%), 100 mg (43.2%) and 50 mg (2.3%) IV daily.

Conclusion: Our results can be utilised to produce a hospital-specific algorithm in terms of Candida-infected patients.

Contribution: These findings contribute to our understanding of prescribing patterns of antifungal agents and the impact thereof on treating Candida spp. Infections.

 


Keywords

echinocandins; candidemia; loading dose; daily dose; appropriate duration

Metrics

Total abstract views: 1048
Total article views: 1071


Crossref Citations

No related citations found.